Amylyx Pharmaceuticals, Inc. AMLX
Institutional shares held
94.1 Million
421K
calls
174K
puts
Total value of holdings
$1.19B
$5.35M
calls
$2.21M
puts
Market Cap
$743M
58,533,200
Shares Out.
Institutional ownership
160.84%
# of Institutions
183
We take great care to ensure that the data presented and summarized in this overview for Amylyx Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMLX
View all-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
-
Commodore Capital LP New York, NY4.08MShares$51.7 Million3.54% of portfolio
-
First Light Asset Management, LLC Edina, MN3.36MShares$42.6 Million5.47% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$35.4 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$33.9 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.54MShares$32.2 Million0.02% of portfolio
Latest Institutional Activity in AMLX
Top Purchases
Top Sells
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AMLX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,580
-3.61%
|
$92,120
$14.35 P/Share
|
|
Sep 30
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,039
-6.19%
|
$168,546
$14.58 P/Share
|
|
Sep 30
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,933
-0.45%
|
$419,062
$14.67 P/Share
|
|
Sep 30
2025
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,558
-3.63%
|
$147,812
$14.65 P/Share
|
|
Sep 30
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,828
-5.62%
|
$123,592
$14.58 P/Share
|
|
Sep 30
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,975
-0.45%
|
$419,650
$14.69 P/Share
|
|
Aug 13
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.72%
|
$120,000
$8.34 P/Share
|
|
Aug 12
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-8.02%
|
$120,000
$8.07 P/Share
|
|
May 22
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
1,000
-0.53%
|
-
|
|
Mar 31
2025
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,896
-3.61%
|
$32,688
$3.47 P/Share
|
|
Mar 31
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,192
-4.66%
|
$27,576
$3.48 P/Share
|
|
Mar 31
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,425
-6.01%
|
$37,275
$3.47 P/Share
|
|
Mar 31
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.47 P/Share
|
|
Mar 31
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.46 P/Share
|
|
Mar 20
2025
|
Bernhardt G Zeiher |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$30,000
$3.7 P/Share
|
|
Mar 06
2025
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+18.48%
|
-
|
|
Mar 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+24.86%
|
-
|
|
Mar 06
2025
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,851
+24.46%
|
-
|
Last 12 Months Summary
Buy / Acquisition
607K
Shares
From
7
Insiders
| Grant, award, or other acquisition | 561K shares |
|---|---|
| Exercise of conversion of derivative security | 36.3K shares |
| Open market or private purchase | 10K shares |
Sell / Disposition
290K
Shares
From
7
Insiders
| Open market or private sale | 261K shares |
|---|---|
| Bona fide gift | 28.9K shares |